Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/31/2022 | $15.00 | Buy | HC Wainwright & Co. |
| 10/19/2021 | $16.00 | Hold → Buy | Maxim Group |
Decoy20 monotherapy induces Partial Response in patient with urothelial cancer and liver metastases Decoy20 combination with PD-1 inhibitor, tislelizumab, demonstrates safety profiles consistent with each agent NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company"), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announces recent updates for the ongoing INDP-D101 clinical trial. "We currently have completed the monotherapy portion of our trial and have initiated seven patients in our initial cohort of combination therapy with tislelizumab, BeOne's anti PD-
NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference. The conference is being held on September 8 – 10, 2025 at the Lotte New York Palace Hotel. Presentation Date:September 8, 2025Time:3:30pm ETLocation:Kennedy I (4th Floor)Webcast Link:https://journey.ct.events/view/8786ffa5-ad42-43a8-984c-41c7b9e3871f A live webcast of the presentation can be accessed on the investor relations section of the Indaptus Therapeutics website. A replay of the webcast will be archived and available following the e
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company"), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announces financial results for the second quarter ended June 30, 2025, and provides a corporate update. Jeffrey Meckler, Indaptus Therapeutics' Chief Executive Officer, commented, "This quarter marks a major clinical inflection point for Indaptus. In under four years since our founding, we have progressed from IND-enabling studies to an active combination trial in patients. This pace of development is a testament to the dedication of the small, but focused
8-K - Indaptus Therapeutics, Inc. (0001857044) (Filer)
S-1/A - Indaptus Therapeutics, Inc. (0001857044) (Filer)
S-1 - Indaptus Therapeutics, Inc. (0001857044) (Filer)
4 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)
4 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)
4 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)
HC Wainwright & Co. resumed coverage of Indaptus Therapeutics with a rating of Buy and set a new price target of $15.00
Maxim Group upgraded Indaptus Therapeutics from Hold to Buy and set a new price target of $16.00
Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- Equity Insider News Commentary – Rising rates of cancer are going to come at a major cost, and it's looking more and more like the solution is going to have to come from the private sector. Recent reports suggest the U.S. government may slash National Cancer Institute (NCI) funding by nearly 40%, while Bloomberg reports growing concern over affordability and access to cancer drugs whose prices are rising sharply. From Wall Street's point of view, the focus needs to shift towards up-and-coming treatments being developed by promising candidates, including from Oncolytics Biot
NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, is pleased to announce the launch of a new social media initiative to provide education and updates about the company. Recognizing the importance of engaging with all stakeholders, Indaptus will generate content on a variety of digital platforms, including X (formerly known as Twitter) and LinkedIn. Indaptus Therapeutics emerges from over a century of groundbreaking advancements in immunotherapy and has built an approach that is designed to stimulate a broad acting effect on the immune sy
NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company") today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update. "We continue to be encouraged by early results from our first cohort of patients in the INDP-D101 trial evaluating Decoy20 for the treatment of solid tumors. As we recently reported and presented at the Society for Immunology in Cancer (SITC) conference, all four first cohort patients have maintained stable disease since receiving their single dose and presented evidence of immune activation, along with short-lived adverse events consistent with Decoy20's mech
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company"), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announces financial results for the second quarter ended June 30, 2025, and provides a corporate update. Jeffrey Meckler, Indaptus Therapeutics' Chief Executive Officer, commented, "This quarter marks a major clinical inflection point for Indaptus. In under four years since our founding, we have progressed from IND-enabling studies to an active combination trial in patients. This pace of development is a testament to the dedication of the small, but focused
Company Achieves Key Clinical Milestone with more than 20 Patients Enrolled in Weekly Dosing Cohort of Phase 1 Trial of Decoy20Pharmacodynamic immune activation biomarker and pharmacokinetics profiles in initial data sets appear to meet or exceed initial expectationsEarly signs of potential benefit emerge with some patients demonstrating Stable Disease NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company") today announces financial results for the fourth quarter and fiscal year ended December 31, 2024 and provides a corporate update. Jeffrey Meckler, Chief Executive Officer of Indaptus, commented, "We continue
Planned industry first clinical trial combining BeiGene's checkpoint inhibitor tislelizumab with Indaptus' broadly targeted, short duration systemic immune stimulator Decoy20 expected to start in 2025 Indaptus Therapeutics Management will hold a conference call on October 22, 2024 at 4:30PM ET to discuss the agreement and future plans NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP), a clinical-stage biotechnology company pioneering innovative cancer and viral infection treatments, today announced a clinical supply agreement with BeiGene. Building on Indaptus' preclinical observation that Decoy20, when combined with a PD-1 inhibitor, induced complete
SC 13D/A - Indaptus Therapeutics, Inc. (0001857044) (Subject)
SC 13D - Indaptus Therapeutics, Inc. (0001857044) (Subject)
SC 13G/A - Indaptus Therapeutics, Inc. (0001857044) (Subject)